Evidence shows that patients with severe asthma are comprised of different phenotypes; one example is an eosinophilic asthma phenotype which has been shown to be associated with asthma severity, late onset disease and refractoriness. 2
The role of IL-5 and eosinophils
IL-5 is the major cytokine responsible for the growth, differentiation, recruitment, activation, and survival of eosinophils.3
Nucala targets IL-5
Nucala, which is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents, and children aged 6 years and older, targets IL-5.6
Raised blood eosinophils have been validated as a biomarker for the patients most likely to benefit from Nucala.7 Patients with blood eosinophils ≥150 cells/μL at initiation of treatment or ≥300 cells/μL in the prior 12 months are predicted to respond to Nucala.6,7
In patients with mean blood eosinophils 290 cells/μL at baseline, Nucala reduced blood eosinophils by 84% at 4 weeks.6
- Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.6
- Only Nucala 100mg SC is licensed in patients aged 12 years and older.
- Only Nucala 40mg SC is licensed in patients aged 6–11 years.
- Moore WC, et al. J Allergy Clin Immunol 2007; 119:405–413.
- Walford H and Doherty T. J Asthma Allergy 2014; 11 : 53-65.
- Weller PF, Spencer LA. Nat Rev Immunol 2017; 17:746–760.
- Malinovschi A, et al. J Allergy Clin Immunol 2013; 132:821–827.
- Wenzel S. Am J Respir Crit Care Med 2005;172(2):149–160.
- Nucala SmPC, 2019. Available at www.medicines.ie Last accessed January 2019.
- Ortega HG et al. Lancet Respir Med 2016; 4:549–556.